Utah Governor Cox and BioUtah Recognize Co-Diagnostics Following Recent JV Announcement in Kingdom of Saudi Arabia

Rhea-AI Summary

Co-Diagnostics (Nasdaq: CODX) was recognized by Utah Governor Spencer Cox and BioUtah following its announced formation of CoMira Diagnostics, a joint venture in the Kingdom of Saudi Arabia on Nov 12, 2025. The company is described as a Utah-born diagnostics firm with a patented platform for molecular diagnostic tests.

The acknowledgment highlights Co-Diagnostics' announced expansion across the Middle East and North Africa and its signing of a definitive JV agreement in the Kingdom of Saudi Arabia, which BioUtah said confirms the company’s growing global presence.

Positive

• Signed a definitive joint venture agreement in the Kingdom of Saudi Arabia on Nov 12, 2025
• Announced geographic expansion across the Middle East and North Africa

Negative

• None.

SALT LAKE CITY, Nov. 12, 2025 /PRNewswire/ -- Governor Spencer Cox joins Kelvyn Cullimore of BioUtah in recognizing Co-Diagnostics, Inc. (Nasdaq: CODX), a Utah diagnostics company with a patented platform for developing advanced molecular diagnostic tests, following its recent announcement of the formation of CoMira Diagnostics, a joint venture (JV) in the Kingdom of Saudi Arabia.

"Co-Diagnostics is a Utah-born company competing on the world stage," said Governor Spencer Cox. "Their expansion across the Middle East and North Africa reflects the strength of Utah's life sciences and the grit of our entrepreneurs. We're proud to see a Utah company building tools that help more patients around the world."

Kelvyn Cullimore, President and CEO of BioUtah, added "BioUtah is proud to count Co-Diagnostics among its Elite members.  Their recent signing of a definitive JV agreement with a company in the Kingdom of Saudi Arabia (KSA) further confirms Co-Diagnostics' expanding leadership and presence on the worldwide stage.  We couldn't be more pleased with the way they represent the Utah life sciences community, one of the fastest growing in the United States."

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.

View original content to download multimedia:https://www.prnewswire.com/news-releases/utah-governor-cox-and-bioutah-recognize-co-diagnostics-following-recent-jv-announcement-in-kingdom-of-saudi-arabia-302612655.html

SOURCE Co-Diagnostics

FAQ

What did Co-Diagnostics (CODX) announce on Nov 12, 2025 about international expansion?

Co-Diagnostics announced the formation of CoMira Diagnostics, a joint venture in the Kingdom of Saudi Arabia, signaling expansion into the Middle East and North Africa.

How did Utah officials respond to Co-Diagnostics' JV announcement in Saudi Arabia?

Utah Governor Spencer Cox and BioUtah publicly recognized Co-Diagnostics for its JV and international expansion on Nov 12, 2025.

What is Co-Diagnostics' core technology mentioned in the Nov 12, 2025 recognition?

Co-Diagnostics is described as having a patented platform for developing advanced molecular diagnostic tests.

Does the Nov 12, 2025 notice state the financial terms of the CoMira Diagnostics JV (CODX)?

No; the recognition notes a definitive JV agreement in the Kingdom of Saudi Arabia but does not disclose financial terms or deal value.

What region will Co-Diagnostics (CODX) target through the CoMira Diagnostics JV?

The announcement indicates expansion focus across the Middle East and North Africa through the Saudi Arabia joint venture.